Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Life Bio’s Trial: Is the FDA Warming to Rejuvenation?

Life Biosciences is advancing the field of rejuvenation therapies by initiating the first human trials of ER-100, an epigenetic treatment aimed at partially reprogramming cells in the human eye. The FDA’s clearance of this Investigational New Drug (IND) filing marks a pivotal shift, as it represents a potential acceptance of cellular reprogramming as a viable therapeutic approach. The trial will focus on patients with optic nerve disorders, such as glaucoma and non-arteritic anterior ischemic optic neuropathy, emphasizing safety and tolerability while exploring routine vision endpoints.

The significance of this trial lies in its potential to redefine the longevity industry, which has historically faced skepticism from regulatory bodies regarding aging as a target for medical intervention. The FDA’s current stance does not recognize aging as a disease; however, by allowing trials that focus on specific conditions, there is an opening for rejuvenation technologies to gain traction. The establishment of the Plausible Mechanism Pathway (PMP) further facilitates this by enabling therapies to be authorized based on mechanistic science, even in small patient cohorts. Success in this trial could catalyze broader acceptance and funding for rejuvenation research, shifting the paradigm from merely managing age-related decline to actively reversing it.

The implications for the field are profound. A successful outcome from the ER-100 trial could not only validate the safety of cellular reprogramming but also encourage the FDA to consider epigenetic reversal as a legitimate clinical endpoint. This would likely lead to a reallocation of research focus towards aging as a root cause of disease, rather than just its symptoms. Furthermore, it could attract institutional investment into the longevity sector, accelerating the development of therapies targeting other organs and ultimately paving the way for systemic rejuvenation approaches. This trial represents a critical step toward integrating rejuvenation technologies into mainstream medicine, potentially reshaping the landscape of aging research and therapeutic development.

Source: lifespan.io